Kiniksa Pharmaceuticals International, plc Revenue 2021–2025
Kiniksa Pharmaceuticals International, plc annual/quarterly revenue history and growth rate from 2021 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Kiniksa Pharmaceuticals International, plc revenue for the quarter ending March 31, 2026 was 214.3 M, a 55.51% increase year-over-year.
- Kiniksa Pharmaceuticals International, plc revenue for the twelve months ending March 31, 2026 was 689.7 M, a 87.55% increase year-over-year.
- Kiniksa Pharmaceuticals International, plc annual revenue for 2025 was 677.6 M, a 60.09% increase from 2024.
- Kiniksa Pharmaceuticals International, plc annual revenue for 2024 was 423.2 M, a 56.60% increase from 2023.
- Kiniksa Pharmaceuticals International, plc annual revenue for 2023 was 270.3 M, a 22.74% increase from 2022.
- Kiniksa Pharmaceuticals International, plc annual revenue for 2022 was 220.2 M.
Kiniksa Pharmaceuticals International, plc (KNSA) — Frequently Asked Questions
Kiniksa Pharmaceuticals International, plc (KNSA) is a publicly traded US company. It has a market capitalization of $4.02B. In fiscal 2025 it reported revenue of $678M and net income of $59M. Explore KNSA's stock price, financial statements, earnings history, margins and key ratios below.
What is Kiniksa Pharmaceuticals International, plc's market cap?
Kiniksa Pharmaceuticals International, plc (KNSA) has a market capitalization of $4.02B.
What is the KNSA stock price?
KNSA trades at $50.90 (+3.31% on the day).
How much revenue does Kiniksa Pharmaceuticals International, plc make?
Kiniksa Pharmaceuticals International, plc reported revenue of $678M in fiscal 2025.
Is KNSA profitable?
In fiscal 2025, Kiniksa Pharmaceuticals International, plc reported net income of $59M.
What is KNSA's P/E ratio?
Based on diluted EPS, KNSA has a price-to-earnings (P/E) ratio of about 67.9.